RAG 21
Alternative Names: RAG-21Latest Information Update: 31 Dec 2024
Price :
$50 *
At a glance
- Originator Ractigen Therapeutics
- Class Drug conjugates; Oligonucleotides; Small interfering RNA
- Mechanism of Action RNA interference; RNA-binding protein FUS inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 19 Nov 2024 Preclinical trials in Amyotrophic lateral sclerosis in China (Intrathecal)
- 19 Nov 2024 RAG 21 receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
- 12 Jan 2023 Ractigen Therapeutics has patent protection for oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use worldwide